Publications by authors named "Kenneth Berger"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

542

Total Likes

8

Extended Reach

32,718

Social Features

11
P
Pharmacodynamics, Safety, and Tolerability of Pyridostigmine Bromide in Heart Failure.
Randal Goldberg, Lucy Norcliffe-Kaufmann, Horacio Kaufmann, Ikoa Jeschke-Lopez, Yu Guo, Kenneth I Berger

Curr Ther Res Clin Exp· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world analysis of the clinical and healthcare burden associated with osteogenesis imperfecta.
Pranav Abraham, Gandarvaka Miles, Natalia Petruski-Ivleva, Kalyani Hawaldar, Cemre Robinson, Kenneth I Berger

Bone· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical burden and healthcare resource utilization associated with achondroplasia: a real-world observational, retrospective cohort study.
Pranav Abraham, Gandarvaka Miles, Natalia Petruski-Ivleva, Kalyani Hawaldar, Cemre Robinson, Kenneth I Berger

Orphanet J Rare Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Switching Therapy From Alglucosidase Alfa to Avalglucosidase Alfa on Respiratory Function in Participants With Late-Onset Pompe Disease: A Post Hoc Analysis From the COMET Trial.
Priya S Kishnani, Matthias Boentert, Stephan Wenninger, Kenneth I Berger, Jérôme Msihid

JIMD Rep· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining clinically meaningful thresholds for forced vital capacity in patients with neuromuscular disorders: Lessons learned from the COMET study in Pompe disease.
Kenneth I Berger, Cristina Ivanescu, Jérôme Msihid, Magali Periquet, Alaa Hamed

J Neuromuscul Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry.
Kenneth I Berger, Yin-Hsiu Chien, Alberto Dubrovsky, Priya S Kishnani, Juan C Llerena

J Neurol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Pompe disease: Unmet needs and emerging therapies" [Mol Genet Metab. 2024 Nov;143(3):108590].
Kelly A George, Allyson L Anding, Arjan van der Flier, Giulio S Tomassy, Kenneth I Berger

Mol Genet Metab· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching to E-cigarettes as Harm Reduction Among Individuals With Chronic Disease Who Currently Smoke: Results of a Pilot Randomized Controlled Trial.
Mahathi Vojjala, Elizabeth R Stevens, Andrew Nicholson, Tucker Morgan, Aayush Kaneria, Kenneth I Berger

Nicotine Tob Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pompe disease: Unmet needs and emerging therapies.
Kelly A George, Allyson L Anding, Arjan van der Flier, Giulio S Tomassy, Kenneth I Berger

Mol Genet Metab· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical insight meets scientific innovation to develop a next generation ERT for Pompe disease.
Priya S Kishnani, Yin-Hsiu Chien, Kenneth I Berger, Nate Thibault, Susan Sparks

Mol Genet Metab· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry.
Kenneth I Berger, Yin-Hsiu Chien, Alberto Dubrovsky, Priya S Kishnani, Juan C Llerena

J Neurol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-hoc Nonparametric Analysis of Forced Vital Capacity in the COMET Trial Demonstrates Superiority of Avalglucosidase Alfa vs Alglucosidase Alfa.
Matthias Boentert, Emmanuelle Salort Campana, Shahram Attarian, Jordi Diaz-Manera, Mazen M Dimachkie, Kenneth I Berger

J Neuromuscul Dis· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trial.
Antonio Toscano, Laurence Pollissard, Jérôme Msihid, Nadine van der Beek, Priya S Kishnani, Kenneth I Berger

Mol Genet Metab· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applying the win ratio method in clinical trials of orphan drugs: an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease.
Matthias Boentert, Kenneth I Berger, Jordi Díaz-Manera, Mazen M Dimachkie, Alaa Hamed

Orphanet J Rare Dis· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lower Airway Dysbiosis Augments Lung Inflammatory Injury in Mild-to-Moderate Chronic Obstructive Pulmonary Disease.
Imran Sulaiman, Benjamin G Wu, Matthew Chung, Bradley Isaacs, Jun-Chieh J Tsay, Kenneth I Berger

Am J Respir Crit Care Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.
Priya S Kishnani, Jordi Diaz-Manera, Antonio Toscano, Paula R Clemens, Shafeeq Ladha, Kenneth I Berger

JAMA Neurol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of small airway dysfunction in unexplained exertional dyspnoea.
Alexis L Sharpe, Joan Reibman, Beno W Oppenheimer, Roberta M Goldring, Mengling Liu, Kenneth I Berger

ERJ Open Res· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel approach to studying effects of inhalational exposure on lung function in civilians exposed to the World Trade Center disaster.
Yuyan Wang, Kenneth I Berger, Yian Zhang, Yongzhao Shao, Roberta M Goldring

Sci Rep· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computer clinical decision support that automates personalized clinical care: a challenging but needed healthcare delivery strategy.
Alan H Morris, Christopher Horvat, Brian Stagg, David W Grainger, Michael Lanspa, Kenneth I Berger

J Am Med Inform Assoc· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Clustering Analysis of Blood Biomarkers in World Trade Center Exposed Community Members with Persistent Lower Respiratory Symptoms.
Gabriele Grunig, Nedim Durmus, Yian Zhang, Yuting Lu, Sultan Pehlivan, Kenneth I Berger

Int J Environ Res Public Health· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COPD in Smoking and Non-Smoking Community Members Exposed to the World Trade Center Dust and Fumes.
Ridhwan Y Baba, Yian Zhang, Yongzhao Shao, Kenneth I Berger, Roberta M Goldring

Int J Environ Res Public Health· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical significance and applications of oscillometry.
David A Kaminsky, Shannon J Simpson, Kenneth I Berger, Peter Calverley, Pedro L de Melo

Eur Respir Rev· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electronic cigarettes as a harm reduction strategy among patients with COPD: protocol for an open-label two arm randomized controlled pilot trial.
Elizabeth R Stevens, Lei Lei, Charles M Cleland, Mahathi Vojjala, Omar El-Shahawy, Kenneth I Berger

Addict Sci Clin Pract· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
Jordi Diaz-Manera, Priya S Kishnani, Hani Kushlaf, Shafeeq Ladha, Tahseen Mozaffar, Kenneth I Berger

Lancet Neurol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis